The Phase 2 study sponsored by King Fahad Medical City aims to evaluate the efficacy of azacytidine in combination with fludarabine, cytarabine, and G-CSF for patients with relapsed or refractory AML. Given the high unmet medical need in this patient population, successful outcomes could position this combination therapy favorably in the competitive landscape of AML treatments. The market for AML therapies is growing, driven by advancements in targeted therapies and immunotherapies. Companies developing treatments for AML should closely monitor this trial's results as they may influence treatment paradigms and competitive positioning. Additionally, the trial's location in Saudi Arabia may provide insights into regional market dynamics and patient access considerations.